Enzo Biochem, Inc. (NYSE:ENZ – Get Free Report) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 478,700 shares, a decrease of 5.0% from the August 31st total of 504,000 shares. Currently, 1.3% of the shares of the company are short sold. Based on an average daily volume of 90,600 shares, the short-interest ratio is presently 5.3 days.
Hedge Funds Weigh In On Enzo Biochem
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd increased its stake in Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares in the last quarter. Wittenberg Investment Management Inc. bought a new stake in Enzo Biochem in the 4th quarter valued at about $95,000. Finally, Renaissance Technologies LLC raised its stake in Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after buying an additional 64,417 shares during the period. 36.90% of the stock is currently owned by institutional investors and hedge funds.
Enzo Biochem Stock Down 0.9 %
NYSE ENZ traded down $0.01 during trading on Monday, hitting $1.12. 81,334 shares of the company’s stock were exchanged, compared to its average volume of 99,829. The stock’s 50 day moving average price is $1.12 and its two-hundred day moving average price is $1.13. Enzo Biochem has a fifty-two week low of $0.99 and a fifty-two week high of $1.50.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on Enzo Biochem
About Enzo Biochem
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Read More
- Five stocks we like better than Enzo Biochem
- Want to Profit on the Downtrend? Downtrends, Explained.
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- What is a Bond Market Holiday? How to Invest and Trade
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Using the MarketBeat Dividend Tax Calculator
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.